Loading news...
BT Group PLC (LSE:BT.A) is heading into its third-quarter results with investor attention once again fixed on Openreach line losses, but analysts at Citi argue that the more important issue lies further downstream in the consumer business. In a note ahead of the results on 5 February, Citi said Openreach broadband losses are likely to dominate headlines, as they have in recent quarters.
Shares of BT Group plc (OTCMKTS:BTGOF - Get Free Report) traded down 5.2% during mid-day trading on Monday. The company traded as low as $2.3750 and last traded at $2.39. 20,294 shares were traded during trading, an increase of 68% from the average session volume of 12,097 shares. The stock had previously closed at
Britain's BT launched a sovereign data platform for its public-sector and business customers on Thursday to store and process their data in the country, responding to increasing demand for higher levels of resilience.
LONDON--(BUSINESS WIRE)--Pindrop, a global leader in authentication and fraud detection, today announced a strategic partnership with BT, one of the world's leading communications service providers, to bring cutting-edge voice security solutions to BT Group's enterprise customers across the UK. This comes as contact centre fraud has surged more than 100% since 2021, growing another 26% year-over-year. Today, 1 in every 599 calls is fraudulent, underscoring the urgent need for advanced protectio.
BT Group plc (OTCPK:BTGOF) Q2 2026 Earnings Call November 6, 2025 5:00 AM EST Company Participants Allison Kirkby - CEO & Director Simon Lowth - CFO & Executive Director Conference Call Participants David Wright - BofA Securities, Research Division James Ratzer - New Street Research LLP Andrew Lee - Goldman Sachs Group, Inc., Research Division Karen Egan - Enders Analysis Ltd Joshua Mills - BNP Paribas, Research Division Max Findlay - Rothschild & Co Redburn, Research Division Maurice Patrick - Barclays Bank PLC, Research Division Carl Murdock-Smith - Citigroup Inc., Research Division Andrew Beale - Arete Research Services LLP Nicholas Lyall - Joh. Berenberg, Gossler & Co. KG, Research Division Presentation Operator Good morning, and welcome, everyone, to BT Group's results presentation for the half year ended 30th of September 2025.
It's never easy to make a silk purse out of a copper wire, and BT Group PLC (LSE:BT.A) latest quarter does little to change the picture. The telecoms group turned in numbers that were broadly in line with expectations, according to UBS, but not enough to shift a market that has grown wary of its patchy revenue performance and the structural headwinds facing its core networks.
BT Group PLC (LSE:BT.A) reported first-half results broadly in line with expectations, as earnings remained flat despite a falling top line, with increased fibre take-up helping offset pressure from competitive markets and legacy declines. Revenue came in at £9.8 billion for the six months to 30 September, down 3% on a year ago, while adjusted EBITDA was unchanged year-on-year at £4.1 billion.
BT Group PLC (LSE:BT.A) second-quarter results this Thursday may reveal more broadband customers switching away from its Openreach arm than investors expect, reckons UBS. Analyst Polo Tang, who has a 'sell' rating and 135p price target on the shares compared to the last close price of 183p, with BT's network infrastructure arm ongoing line losses also signalling mounting competitive pressure and revenue risk that recent broadband price cuts and cost savings may not be enough to offset.
Stockholm, Sweden – October 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that it has exercised its pro rata participation of SEK 7.5 million in BOOST Pharma's latest financing. In total, BOOST Pharma's financing, structured as a convertible loan, brings SEK 15 million to the company. The investment supports the continued preparation for Phase III clinical development of BT-101, a pioneering stem cell-based therapy for osteogenesis imperfecta (OI), also known as brittle bone disease. BOOST Pharma, a clinical-stage biopharmaceutical company, is advancing BT-101 as a novel mesenchymal stem cell therapy for infants born with osteogenesis imperfecta (OI) , a condition characterized by fragile bones, frequent fractures and bone deformity. The treatment is designed to reduce fracture frequency in affected pediatric patients providing a possible treatment advantage in the early years of life, when most fractures occur. With the proceeds from this financing, BOOST Pharma aims to accelerate the ongoing clinical program and move closer to providing the first disease-modifying therapy for OI.
BT Group PLC (LSE:BT.A) is weighing a move into the low-cost mobile market, according to a report from the Financial Times. The UK's largest broadband provider has been mulling options including launching a new brand or snapping up an existing MVNO (mobile virtual network operator), people familiar with the matter said.
Britain's largest broadband provider BT Group is mulling the launch of a low-cost mobile brand, the Financial Times reported on Tuesday, citing people familiar with the matter.
Momentum in UK and European dealmaking is expected to accelerate in what Morgan Stanley analysts believe will be a "multi-year global M&A rebound", where mining, telecoms and defence sectors are seen as most likely to benefit. European corporate merger and acquisition activity is up around 5% this year compared to last, the bank said in its latest global M&A analysis, with deal volume up 43% when including private equity and venture capital purchases.
The rollout is progressing well, and the undue burden ending soon enough should start to shrink discounts to less burdened peers. Rates are coming down. Not a bad thing given a fair amount of the debt burden is variable rate. Not a phenomenal revenue performance, but not bad either and we see some benefits on the horizon for the stock.
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy LUND, SE / ACCESS Newswire / October 20, 2025 / Transgene (Euronext Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class antibodies for cancer immunotherapy, are jointly presented a poster at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting on updated clinical results and positive antitumoral activity of BT-001 in patients with advanced refractory tumors. The data show that intra-tumoral (IT) BT-001 injection in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) intravenous (IV) anti-PD-1 therapy KEYTRUDA® (pembrolizumab [1] ), was well tolerated and showed positive local, abscopal and sustained antitumoral activity in injected and non-injected lesions.
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy Strasbourg, France, and Lund, Sweden, October 20, 2025, 08:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class antibodies for cancer immunotherapy, jointly presented a poster at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting on updated clinical results and positive antitumoral activity of BT-001 in patients with advanced refractory tumors.
- Updated clinical data on BT-001 in combination with pembrolizumab to be presented in a poster - Tumor shrinkage observed in both injected and non-injected lesions LUND, SE / ACCESS Newswire / October 13, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will jointly present a poster on translational data and updated clinical results from the Phase 1 study of BT-001 at the European Society for Medical Oncology(ESMO) Annual Meeting. ESMO will take place in Berlin, Germany, from October 17 to 21, 2025.
Poster presentation on BT-001 in combination with pembrolizumab has shown tumor shrinkage in both injected and non-injected lesions Strasbourg, France, and Lund, Sweden, October 13, 2025, 8:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, will jointly present a poster on translational data and updated clinical results from the Phase I study of BT-001 at the upcoming European Society for Medical Oncology (ESMO) Annual Meeting.
Physics jokes are not standard fare in City research notes, but Deutsche Bank could not resist. Its analyst Robert Grindle has likened BT Group PLC's (LSE:BT.A) new chief executive to a “quantum-confined Stark effect”, coining the “BT-confined Allison Effect”, shorthand for the fresh energy of Allison Kirkby and how it may be altering investor perception of the group.
VODNJAN, Croatia--(BUSINESS WIRE)--BT and Infobip have announced the global expansion of their partnership to deliver AI-powered advanced communication services to multinational businesses worldwide. The extended partnership builds on a successful collaboration in the UK, announced in 2022, and combines BT's Global Voice and inbound contact capabilities with Infobip's market-leading cloud communications platform. Together, the two companies will drive innovation in global connectivity, providin.
Analyst coverage of BT Group PLC (LSE:BT.A) had a negative hue to it on Thursday, with both Citi and Deutsche Bank reiterating 'sell' recommendations. The American bank, with a 140p target price, cautioned that the telco faces a “risk event” when it reports second-quarter results on November 6.